person · Reporting owner

SEIDENBERG BETH C

Disclosed activity across 11 companies

Tapewire entity: 13954
SEC CIK: 0001184592

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Atara Biotherapeutics, Inc.ATRA · Entity 6828	Director	May 31, 2023	June 03, 2023
Epizyme, Inc.EPZM · Entity 12703	Director	June 30, 2019	July 02, 2019
Kyverna Therapeutics, Inc.KYTX · Entity 5452	Director	May 27, 2026	May 29, 2026
Latigo Biotherapeutics, Inc.LTGO · Entity 4709	Director · 10% owner	August 10, 2026	August 11, 2026
Progyny, Inc.PGNY · Entity 4521	Director	May 23, 2024	May 29, 2024
Sagimet Biosciences Inc.SGMT · Entity 5273	Director	June 12, 2026	June 15, 2026
Vera Therapeutics, Inc.VERA · Entity 4358	Director	May 21, 2026	May 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atara Biotherapeutics, Inc.

Report date May 31, 2023 · Filed June 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	115,689	Reported balance After 2023-05-31 transaction · row 1 1 source row Row 1 · 2023-05-31 · Grant · Acquired 57,000 · Balance 115,689 F1: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2033-05-30	Direct	79,500	Reported balance After 2023-05-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-05-31 · Grant · Acquired 79,500 · Balance 79,500 F2: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,822,228	Reported balance Holding disclosure · report date 2023-05-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,822,228 F3: The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
Common StockSEC Table I · non-derivative	IndirectSee footnote	54,422	Reported balance Holding disclosure · report date 2023-05-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 54,422 F4: The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
Common StockSEC Table I · non-derivative	IndirectSee footnote	197	Reported balance Holding disclosure · report date 2023-05-31 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 197 F5: Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.
Common StockSEC Table I · non-derivative	IndirectSee footnote	197	Reported balance Holding disclosure · report date 2023-05-31 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 197 F6: Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

F2: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

F3: The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.

F4: The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.

F5: Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.

F6: Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.

Epizyme, Inc.

Report date June 30, 2019 · Filed July 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	Direct	8,481	Reported balance After 2019-06-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-06-30 · Grant · Acquired 1,010 · Balance 8,481 F1: The shares were issued to the Reporting Person pursuant to her election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $12,687.50 for Board services for the second fiscal quarter of 2019. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter.
Common Stock, par value $0.0001SEC Table I · non-derivative	IndirectSee Notes 2 and 3	4,115,555	Reported balance Holding disclosure · report date 2019-06-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,115,555 F2: The shares consist of 3,838,167 shares of common stock held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") and 277,388 shares of common stock beneficially owned by individuals and entities associated with Kleiner Perkins Caulfield & Byers (collectively, "KPCB Direct"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The managing member of KPCB XIII is KPCB XIII Associates, LLC, which has sole voting and dispositive power over the shares held by KPCB XIII. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of her pecuniary interest therein. F3: The Reporting Person disclaims beneficial ownership over all Issuer shares held for convenience in the name of "KPCB Holdings, Inc. as nominee," except to the extent of her pecuniary interest therein and this filing is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued to the Reporting Person pursuant to her election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $12,687.50 for Board services for the second fiscal quarter of 2019. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter.

F2: The shares consist of 3,838,167 shares of common stock held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") and 277,388 shares of common stock beneficially owned by individuals and entities associated with Kleiner Perkins Caulfield & Byers (collectively, "KPCB Direct"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The managing member of KPCB XIII is KPCB XIII Associates, LLC, which has sole voting and dispositive power over the shares held by KPCB XIII. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of her pecuniary interest therein.

F3: The Reporting Person disclaims beneficial ownership over all Issuer shares held for convenience in the name of "KPCB Holdings, Inc. as nominee," except to the extent of her pecuniary interest therein and this filing is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.

Kyverna Therapeutics, Inc.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,727	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27	Direct	20,582	Reported balance After 2026-05-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,787,940	Reported balance Holding disclosure · report date 2026-05-27 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,787,940 F3: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	869,317	Reported balance Holding disclosure · report date 2026-05-27 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 869,317 F4: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

F3: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.

F4: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.

Latigo Biotherapeutics, Inc.

Report date August 10, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,368,532	Reported balance After 2026-08-10 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-10 · Conversion · Acquired 938,979 · Balance 1,368,532 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,916,374	Reported balance After 2026-08-10 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-08-10 · Conversion · Acquired 3,547,842 · Balance 4,916,374 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,944,009	Reported balance After 2026-08-10 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-10 · Conversion · Acquired 1,027,635 · Balance 5,944,009 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,510,927	Reported balance After 2026-08-10 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-08-10 · Conversion · Acquired 3,464,072 · Balance 3,510,927 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,995,328	Reported balance After 2026-08-10 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-08-10 · Conversion · Acquired 1,484,401 · Balance 4,995,328 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,160,847	Reported balance After 2026-08-10 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-08-10 · Conversion · Acquired 165,519 · Balance 5,160,847 F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,094,813	Reported balance After 2026-08-10 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2026-08-10 · Conversion · Acquired 2,066,857 · Balance 2,094,813 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series Seed Convertible StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-08-10 · Conversion · Disposed 938,979 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-08-10 · Conversion · Disposed 3,547,842 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-08-10 · Conversion · Disposed 1,027,635 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-08-10 · Conversion · Disposed 3,464,072 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-08-10 · Conversion · Disposed 2,066,857 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-08-10 · Conversion · Disposed 1,484,401 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Convertible Promissory NoteSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-08-10 · Conversion · Disposed 165,519 · Balance 0 F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.

F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Progyny, Inc.

Report date May 23, 2024 · Filed May 29, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	43,416	Reported balance After 2024-05-23 transaction · row 1 1 source row Row 1 · 2024-05-23 · Grant · Acquired 7,206 · Balance 43,416 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-05-22	Direct	26,926	Reported balance After 2024-05-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-23 · Grant · Acquired 26,926 · Balance 26,926 F4: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,074,615	Reported balance Holding disclosure · report date 2024-05-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 5,074,615 F2: These shares are held directly by KPCB XIII and individuals and entities associated with KPCB. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). Voting and dispositive control over the shares are shared by individual managing directors of XIII Associates, none of whom have veto power. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of the Reporting Person's pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	227,906	Reported balance Holding disclosure · report date 2024-05-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 227,906 F3: These shares are held by The Seidenberg/Vogel Revocable Trust u/a/d 3/6/03, as amended and restated on 6/16/2020. Paul S. Vogel and Beth C. Seidenberg are the trustees of the trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.

F2: These shares are held directly by KPCB XIII and individuals and entities associated with KPCB. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). Voting and dispositive control over the shares are shared by individual managing directors of XIII Associates, none of whom have veto power. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of the Reporting Person's pecuniary interest therein.

F3: These shares are held by The Seidenberg/Vogel Revocable Trust u/a/d 3/6/03, as amended and restated on 6/16/2020. Paul S. Vogel and Beth C. Seidenberg are the trustees of the trust.

F4: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.

Sagimet Biosciences Inc.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11	Direct	39,567	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Vera Therapeutics, Inc.

Report date May 21, 2026 · Filed May 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20	Direct	17,084	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-05-21 transaction · row 1 1 source row Row 1 · 2025-05-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-05-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-05-21 · Disposition to issuer · Disposed 9,790,729 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person is the Managing Director of Westlake GP II and has sole voting and dispositive power over the shares held by Westlake Fund II, and disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of the Reporting Person's pecuniary interest therein, if any.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	Reported balance After 2025-05-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F3: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06	Direct	Reported balance After 2025-05-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person is the Managing Director of Westlake GP II and has sole voting and dispositive power over the shares held by Westlake Fund II, and disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of the Reporting Person's pecuniary interest therein, if any.

F3: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

AMGEN INC

Report date December 31, 2004 · Filed January 04, 2005

Section 16 reporting ended · disclosed 2005-01-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,343	Ending reported balance After 2004-12-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2004-12-31 · Tax withholding · Disposed 6,121 · Balance 20,720 Row 2 · 2004-12-31 · Disposition to issuer · Disposed 5,377 · Balance 15,343

ARMO BioSciences, Inc.

Report date June 22, 2018 · Filed June 22, 2018

Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy KPCB Holdings, Inc., as nominee	0	Reported balance After 2018-06-22 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-06-22 · Other · Disposed 4,266,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F4: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F5: (Continued from Footnote 4) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2028-03-25	Direct	0	Reported balance After 2018-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F4: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates").

F5: (Continued from Footnote 4) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF.

TESARO, Inc.

Report date January 22, 2019 · Filed January 24, 2019

Section 16 reporting ended · disclosed 2019-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 45,907 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2019-01-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-01-22 · Other · Disposed 1,994,768 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2: The shares are held directly by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"). The managing member of KPCB XIV is KPCB XIV Associates, LLC ("KPCB XIV Associates"), of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2019-01-22 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2019-01-22 · Other · Disposed 168,755 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F4: The shares are held directly by KPCB XIV Founders Fund, LLC ("KPCB XIV Founders"). The managing member of KPCB XIV Founders is KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2019-01-22 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2019-01-22 · Other · Disposed 10,998 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F5: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."
Common StockSEC Table I · non-derivative	IndirectBy Michael J. Seidenberg Irrevocable Trust	Reported balance After 2019-01-22 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-01-22 · Other · Disposed 868 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F6: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Michael J. Seidenberg Irrevocable Trust	Reported balance After 2019-01-22 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2019-01-22 · Other · Disposed 868 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F6: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Director Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F7: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F8: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.22 · Expires 2023-06-03	Direct	Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2024-06-01	Direct	Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.77 · Expires 2025-06-01	Direct	Reported balance After 2019-01-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.27 · Expires 2026-06-01	Direct	Reported balance After 2019-01-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01	Direct	Reported balance After 2019-01-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01	Direct	Reported balance After 2019-01-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: The shares are held directly by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"). The managing member of KPCB XIV is KPCB XIV Associates, LLC ("KPCB XIV Associates"), of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."

F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.

F4: The shares are held directly by KPCB XIV Founders Fund, LLC ("KPCB XIV Founders"). The managing member of KPCB XIV Founders is KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."

F5: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."

F6: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

F7: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F8: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 22, 2019 Filed Jan 24, 2019 17:30 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	10,998	$75.00	$824,850.00	Disclosure SEC source: 0001123292-19-000190 · edgar.xml · nonDerivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F3 · ownership.nature: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F5 · ownership.nature: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." Read SEC document
January 22, 2019 Filed Jan 24, 2019 17:30 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	168,755	$75.00	$12,656,625.00	Disclosure SEC source: 0001123292-19-000190 · edgar.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F3 · ownership.nature: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F4 · ownership.nature: The shares are held directly by KPCB XIV Founders Fund, LLC ("KPCB XIV Founders"). The managing member of KPCB XIV Founders is KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." Read SEC document
January 22, 2019 Filed Jan 24, 2019 17:30 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	1,994,768	$75.00	$149,607,600.00	Disclosure SEC source: 0001123292-19-000190 · edgar.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2 · ownership.nature: The shares are held directly by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"). The managing member of KPCB XIV is KPCB XIV Associates, LLC ("KPCB XIV Associates"), of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." F3 · ownership.nature: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. Read SEC document
January 22, 2019 Filed Jan 24, 2019 17:30 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	45,907	$75.00	$3,443,025.00	Disclosure SEC source: 0001123292-19-000190 · edgar.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
July 02, 2018 Filed Jul 2, 2018 21:42 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantCommon Stock, par value $0.0001	3,247	$13.55	$43,996.85	Disclosure SEC source: 0001209191-18-040459 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,447 F1 · security: The shares were issued to the Reporting Person pursuant to her election under the Company's director compensation program in lieu of cash fees of $44,000 for Board services. Read SEC document
June 22, 2018 Filed Jun 22, 2018 17:11 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	Disposition to issuerStock Option (right to buy) · Derivative	18,000	$10.03 Strike: $39.97	$180,540.00	Disclosure SEC source: 0000899243-18-017712 · doc4.xml · derivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-03-25 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
June 22, 2018 Filed Jun 22, 2018 17:11 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	OtherCommon Stock	4,266,683	$50.00	$213,334,150.00	Disclosure SEC source: 0000899243-18-017712 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F4 · ownership.nature: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F5 · ownership.nature: (Continued from Footnote 4) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
June 14, 2018 Filed Jun 18, 2018 23:21 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $45.65	$0.00	Disclosure SEC source: 0001209191-18-038423 · doc4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F6 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document
June 14, 2018 Filed Jun 18, 2018 23:21 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	1,500	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038423 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,189 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document
June 01, 2018 Filed Jun 5, 2018 19:01 UTC	TESARO, Inc. TSRO · Entity 160894	GrantDirector Restricted Stock Units · Derivative	4,052	$0.00	$0.00	Disclosure SEC source: 0001104659-18-038390 · a4.xml · derivative · entry 8 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052 Underlying: Common Stock · 4,052 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of TESARO common stock. F9 · derivative.exercise_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. F9 · derivative.expiration_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2018 Filed Jun 5, 2018 19:01 UTC	TESARO, Inc. TSRO · Entity 160894	GrantDirector Nonqualified Stock Option (right to buy) · Derivative	7,209	$0.00 Strike: $46.89	$0.00	Disclosure SEC source: 0001104659-18-038390 · a4.xml · derivative · entry 7 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F7 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2018 Filed Jun 5, 2018 19:01 UTC	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	1,332	$0.00	$0.00	Disclosure SEC source: 0001104659-18-038390 · a4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,907 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash, and has elected to defer delivery of that common stock until the date that she separates from service on the Issuer's board of directors. Read SEC document
May 18, 2018 Filed May 31, 2018 20:26 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001209191-18-034366 · doc4.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-17 F1 · derivative.exercise_date: This option was granted on May 18, 2018, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on May 18, 2019 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document
March 26, 2018 Filed Mar 28, 2018 16:55 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $39.97	$0.00	Disclosure SEC source: 0000899243-18-008730 · doc4.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-03-25 F1 · derivative.exercise_date: 1/36th of the shares of common stock subject to the option vest on the last day of the calendar month in which the option was granted, and 1/36th of the shares subject to the option vest on the last day of the 35 calendar months immediately thereafter. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionSeries C-1 Convertible Preferred Stock · Derivative	326,242	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · derivative · entry 7 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 326,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionSeries C Convertible Preferred Stock · Derivative	403,097	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 403,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionSeries B-1 Convertible Preferred Stock · Derivative	355,429	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · derivative · entry 5 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 355,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionSeries B Convertible Preferred Stock · Derivative	1,296,248	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · derivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 1,296,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionSeries A Convertible Preferred Stock · Derivative	1,212,494	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · derivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 1,212,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionSeries A-1 Convertible Preferred Stock · Derivative	673,173	$0.00	$0.00	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · derivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 0 Underlying: Common Stock · 673,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · derivative.exercise_price: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. F2 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
January 30, 2018 Filed Jan 30, 2018 17:10 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	ConversionCommon Stock	4,266,683	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-002284 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By KPCB Holdings, Inc., as nominee Disclosed balance after: 4,266,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A-1, A, B, B-1, C and C-1 Convertible Preferred Stock. F2 · price: Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F4 · ownership.nature: (Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF. Read SEC document
December 14, 2017 Filed Dec 15, 2017 21:20 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	13,219	$0.00	$0.00	Disclosure SEC source: 0001144204-17-064050 · tv481549_4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,998 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by KPCB XIV Associates, LLC ("KPCB XIV Associates") without consideration to its members. F2 · shares: Includes 24,217 shares acquired on September 11, 2017 pursuant to a pro-rata in-kind distribution made by Kleiner Perkins Caufield & Byers XIV, LLC without consideration to its members, including KPCB XIV Associates. F3 · ownership.nature: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	663	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 7 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Samuel B. Seidenberg Irrevocable Trust Disclosed balance after: 868 F9 · kind: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the Associates Distribution. F10 · ownership.nature: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	663	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Michael J. Seidenberg Irrevocable Trust Disclosed balance after: 868 F9 · kind: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the Associates Distribution. F10 · ownership.nature: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	22,516	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 5 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,575 F9 · kind: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the Associates Distribution. Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	204,166	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by KPCB XIV Associates without consideration to its members (the "Associates Distribution"). F7 · ownership.nature: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	204,166	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 204,166 F6 · kind: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares from KPCB XIV in the Fund Distribution. F7 · ownership.nature: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	58,500	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 168,755 F4 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by KPCB XIV Founders Fund, LLC ("KPCB XIV Founders") without consideration to its members. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership over all Issuer shares held for convenience in the name of "KPCB Holdings, Inc. as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F5 · ownership.nature: The shares are held directly by KPCB XIV Founders. The managing member of KPCB XIV Founders is KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc. as nominee." Read SEC document
September 11, 2017 Filed Sep 11, 2017 19:45 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	667,283	$0.00	$0.00	Disclosure SEC source: 0001144204-17-047522 · v474991_4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,018,985 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV") without consideration to its members (the "Fund Distribution"). F2 · ownership.nature: The shares are held directly by KPCB XIV. The managing member of KPCB XIV is KPCB XIV Associates, LLC ("KPCB XIV Associates"), of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc. as nominee." F3 · ownership.nature: The Reporting Person disclaims beneficial ownership over all Issuer shares held for convenience in the name of "KPCB Holdings, Inc. as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. Read SEC document
June 22, 2017 Filed Jun 26, 2017 17:53 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $13.65	$0.00	Disclosure SEC source: 0001209191-17-041809 · doc4.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option was granted on June 22, 2017, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on June 22, 2018 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document
June 08, 2017 Filed Jun 12, 2017 21:31 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNonQualified Stock Option (Right to Buy) · Derivative	21,500	$0.00 Strike: $13.20	$0.00	Disclosure SEC source: 0001209191-17-039241 · doc4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2024-06-08 F6 · derivative.exercise_date: The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document
June 08, 2017 Filed Jun 12, 2017 21:31 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-039241 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,689 F1 · shares: These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document
June 01, 2017 Filed Jun 5, 2017 18:16 UTC	TESARO, Inc. TSRO · Entity 160894	GrantDirector Nonqualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $149.22	$0.00	Disclosure SEC source: 0001104659-17-037539 · a4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F6 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2017 Filed Jun 5, 2017 18:16 UTC	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	402	$0.00	$0.00	Disclosure SEC source: 0001104659-17-037539 · a4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,059 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash, and has elected to defer delivery of that common stock until the date that she separates from service on the Issuer's board of directors. Read SEC document
January 03, 2017 Filed Jan 5, 2017 22:49 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNonQualified Stock Option (Right to Buy) · Derivative	5,500	$0.00 Strike: $15.08	$0.00	Disclosure SEC source: 0001209191-17-002279 · doc4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-01-03 F6 · derivative.exercise_date: The option shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service. Read SEC document
January 03, 2017 Filed Jan 5, 2017 22:49 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-002279 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,689 F1 · shares: These restricted stock units shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service. Read SEC document
December 31, 2004 Filed Jan 4, 2005 19:41 UTC	AMGEN INC AMGN · Entity 2832	Disposition to issuerCommon Stock	5,377	$0.00	$0.00	Disclosure SEC source: 0001181431-05-000793 · rrd63282.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Sr VP, Dev & Chief Medical Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,343 Read SEC document
December 31, 2004 Filed Jan 4, 2005 19:41 UTC	AMGEN INC AMGN · Entity 2832	Tax withholdingCommon Stock	6,121	$64.15	$392,662.15	Disclosure SEC source: 0001181431-05-000793 · rrd63282.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Sr VP, Dev & Chief Medical Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,720 Read SEC document
March 15, 2004 Filed Mar 17, 2004 16:47 UTC	AMGEN INC AMGN · Entity 2832	GrantNQSO (Right to Buy) · Derivative	48,319	$0.00 Strike: $59.48	$0.00	Disclosure SEC source: 0001181431-04-016115 · rrd36907.xml · derivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Sr VP, Dev & Chief Medical Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,319 Underlying: Common Stock · 48,319 shares Expires 2011-03-15 F1 · derivative.exercise_date: (3.15.04) The option becomes exercisable in five as nearly equal annual installments as possible, beginning on March 15, 2005. Read SEC document
March 15, 2004 Filed Mar 17, 2004 16:47 UTC	AMGEN INC AMGN · Entity 2832	GrantISO (Right to Buy) · Derivative	1,681	$0.00 Strike: $59.48	$0.00	Disclosure SEC source: 0001181431-04-016115 · rrd36907.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Sr VP, Dev & Chief Medical Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681 Underlying: Common Stock · 1,681 shares Expires 2011-03-15 Read SEC document
January 14, 2004 Filed Jan 15, 2004 17:33 UTC	AMGEN INC AMGN · Entity 2832	Tax withholdingCommon Stock	1,858	$64.05	$119,004.90	Disclosure SEC source: 0001181431-04-002798 · rrd29162.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Sr VP, Dev & Chief Medical Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,335 Read SEC document
July 01, 2003 Filed Jul 2, 2003 20:18 UTC	AMGEN INC AMGN · Entity 2832	GrantNQSO (Right to Buy) · Derivative	98,482	$0.00 Strike: $65.85	$0.00	Disclosure SEC source: 0001181431-03-012795 · rrd11691.xml · derivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Sr VP Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,482 Underlying: Common Stock · 98,482 shares Expires 2010-07-01 F2 · price: 0 F1 · derivative.exercise_date: (BCS-07/03-NQSO) The option becomes exercisable for 20,000 shares on July 1, 2004; 20,000 shares on July 1, 2005; 20,000 shares on July 1, 2006; 20,000 shares on July 1, 2007; and 18,482 shares on July 1, 2008, respectively. Read SEC document
July 01, 2003 Filed Jul 2, 2003 20:18 UTC	AMGEN INC AMGN · Entity 2832	GrantISO (Right to Buy) · Derivative	1,518	$0.00 Strike: $65.85	$0.00	Disclosure SEC source: 0001181431-03-012795 · rrd11691.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Sr VP Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518 Underlying: Common Stock · 1,518 shares Expires 2010-07-01 F2 · price: 0 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.